February 8, 2018 / 1:19 PM / in 8 months

BRIEF-Rexahn Pharmaceuticals Collaborates With Zhejiang Haichang Biotechnology

Feb 8 (Reuters) - Rexahn Pharmaceuticals Inc:

* REXAHN PHARMACEUTICALS ANNOUNCES COLLABORATION WITH ZHEJIANG HAICHANG BIOTECHNOLOGY CO., LTD. FOR THE DEVELOPMENT OF RX-0201 (ARCHEXIN®) FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA

* REXAHN PHARMACEUTICALS INC - IN CONNECTION WITH AGREEMENT WITH HAICHANG, REXAHN PLANS TO DISCONTINUE INTERNALLY FUNDED PROGRAMS OF ARCHEXIN

* REXAHN PHARMACEUTICALS INC - REXAHN WILL ALSO CEASE ENROLLMENT IN CURRENT PHASE IIA CLINICAL STUDY OF ARCHEXIN IN METASTATIC RENAL CELL CARCINOMA

* REXAHN PHARMACEUTICALS - ‍UNDER TERMS OF DEAL, HAICHANG WILL DEVELOP A NANO-LIPOSOMAL FORMULATION OF RX-0201 USING ITS PROPRIETARY QTSOME TECHNOLOGY​

* REXAHN - PARTIES TO SHARE DOWNSTREAM LICENSING FEES, ROYALTIES PAID RELATED TO DEVELOPMENT,COMMERCIALIZATION OF NANO-LIPOSOMAL FORMULATION OF RX-0201 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below